Clinical Trial: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221253) titled 'A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)' on Oct. 01.

Brief Summary: The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Condition: Biliary Tract Cancer

Intervention: DRUG: Rilvegostomig

Rilvegostomig IV (intravenous) Q3W

DRUG: Durvalumab

Durvalumab 1500mg IV (intravenous) Q3W for up to 8 cycles (21days). Then Q4W.

DRUG: Gemc...